Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Summary by Barchart.com
Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

Barchart.comBarchart.com

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Barchart.com broke the news in on Thursday, March 13, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Eli Lilly icon

Eli Lilly

Thousand Oaks icon

Thousand Oaks

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal